Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression

Molecular Cancer Therapeutics

Volumn 8, Issue 9, 2009, Pages 2718-2725

  Yeh, Cheng Chang ^a   Deng, Yi Ting ^a,b   Sha, De Yuan ^a   Hsiao, Michael ^c   Kuo, Mark Yen Ping ^a,b,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; CASPASE 8; CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; FAS LIGAND; PROTEIN P53; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; HYDROXAMIC ACIDS; IN SITU NICK-END LABELING; MOUTH NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 70349481308     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0211     Document Type: Article

References (34)

1. Notani PN. Epidemiology and prevention of head and neck cancer: a global view. In: Saranath D, editor. Contemporary issues in oral cancer. New Delhi: Oxford University Press; 2000, p. 1-29.
2. Ries LAG, Kosary CL, Hankey BF, Miller BA, Clogg L, Edwards BK, editors. SEER cancer statistics review, 1973-1996. Bethesda: National Cancer Institute; 1999.
3. Clayman GL, Lippman SM, Laramore GE, Hong WK. Head and neck cancer. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum R, editors. Cancer medicine. Philadelphia: Williams and Wilkins; 1996, p. 1645-1709.
4. Neville BW, Day TA. Oral cancer and precancerous lesions [review]. CA Cancer J Clin 2002;52:195-215.
5. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002;24:165-180
6. Kim R, Emi M, Tanabe K, Uchida Y, Arihiro K. The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment [review]. Eur J Surg Oncol 2006;32:269-277
7. Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease [review]. Pharmacol Rev 2005;57:187-215. (Pubitemid 41043884)
8. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162
9. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163 (Pubitemid 29068521)
10. Fukuda M, Hamao A, Tanaka A, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/APO2L) and its receptors expression in human squamous cell carcinoma of the oral cavity. Oncol Rep 2003;10:1113-1119
11. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev 2006;6:38-51. (Pubitemid 43054973)
12. Chang HH, Chiang CP, Hung HC, Lin CY, Deng YT, Kuo MY. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 2009;45:610-614
13. Amin HM, Saeed S, Alkan S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 2001;115:287-297 (Pubitemid 34203490)
14. Henderson C , Mizzau M, Paroni G, Maestro R, Schneider C , Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003;278:12579-12589 (Pubitemid 36800248)
15. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77-84. (Pubitemid 40215841)
16. Sonnemann J, Hartwig M, Plath A, Saravana Kumar K, Müller C, Beck JF. Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. Cancer Lett 2006;2322:148-160 (Pubitemid 43170964)
17. Gillenwater AM, Zhong M, Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 2007;6:2967-2975 (Pubitemid 350206775)
18. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003;101:4055-4062 (Pubitemid 36857886)
19. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001;98:10833-10838 (Pubitemid 32878706)
20. Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 2007;30:1181-1188
21. Jia LQ, Osada M, Ishioka C, et al. Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 1997;19:243-253 (Pubitemid 27392003)
22. Ohnishi K, Ota I, Takahashi A, Yane K, Matsumoto H, Ohnishi T. Transfection of mutant p53 gene depresses X-ray- or CDDP-induced apoptosis in a human squamous cell carcinoma of the head and neck. Apoptosis 2002;7:367-372 (Pubitemid 34832261)
23. Lee J, Huang MS, Yang IC, et al. Essential roles of caspases and their upstream regulators in rotenone-induced apoptosis. Biochem Biophys Res Commun 2008;371:33-38
24. Kok SH, Cheng SJ, Hong CY, et al. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett 2005;217:43-52. (Pubitemid 39642865)
25. Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res 2001;61:2704-2712 (Pubitemid 32685858)
26. Jang YJ, Park KS, Chung HY, Kim HI. Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities. Cancer Lett 2003;194:107-117
27. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Cancer Res 1999;59:734-741
28. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000;96:3900-3906
29. Sonnemann J, Gänge J, Kumar KS, Müller C, Bader P, Beck JF. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines [review]. Invest New Drugs 2005;23:99-109. (Pubitemid 40386226)
30. Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005;24:4609-4623 (Pubitemid 41032599)
31. Bossi G, Sacchi A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 2007;29:272-284 (Pubitemid 46339325)
32. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000;19:1735-1743 (Pubitemid 30200979)
33. Johnston JB, Kabore AF, Strutinsky J, et al. Role of the TRAIL/APO2- L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 2003;22:8356-8369 (Pubitemid 37485528)
34. Meng RD, El-Deiry WS. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-γ. Exp Cell Res 2001;262:154-169